Discussion
A global, late-stage clinical trial testing the injection therapy apazunersen (GTX-102) in children with Angelman syndrome has failed to meet its main and secondary goals, according to developer Ultragenyx Pharmaceutical. Data from the Phase 3 trial, which tested the once-promising therapy candidate in more than 100 youngsters…